ABIVAX Société Anonyme (NASDAQ:ABVX) Short Interest Down 29.5% in April

ABIVAX Société Anonyme (NASDAQ:ABVX) was the target of a significant decrease in short interest in April. As of April 15th, there was short interest totalling 113,800 shares, a decrease of 29.5% from the March 31st total of 161,500 shares. Based on an average trading volume of 74,700 shares, the short-interest ratio is currently 1.5 days. Currently, 0.2% of the company’s stock are short sold.

Hedge Funds Weigh In On ABIVAX Société Anonyme

A number of institutional investors have recently bought and sold shares of ABVX. Franklin Resources Inc. acquired a new position in ABIVAX Société Anonyme during the fourth quarter worth approximately $13,630,000. Capstone Investment Advisors LLC acquired a new position in ABIVAX Société Anonyme during the fourth quarter worth approximately $618,000. Ghisallo Capital Management LLC acquired a new position in ABIVAX Société Anonyme during the fourth quarter worth approximately $642,000. Commodore Capital LP acquired a new position in ABIVAX Société Anonyme during the fourth quarter worth approximately $20,277,000. Finally, Blackstone Inc. acquired a new position in ABIVAX Société Anonyme during the fourth quarter worth approximately $25,345,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

ABIVAX Société Anonyme Stock Performance

Shares of NASDAQ ABVX opened at $15.78 on Friday. The stock’s 50 day simple moving average is $14.44. ABIVAX Société Anonyme has a twelve month low of $7.99 and a twelve month high of $17.02.

Analysts Set New Price Targets

Separately, Morgan Stanley upped their target price on ABIVAX Société Anonyme from $15.00 to $16.00 and gave the stock an “equal weight” rating in a report on Thursday, April 11th.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.